Targeting protein kinase C subtypes in pancreatic cancer

References

• Evans JD, Cornford PA, Dodson A, et al. Expression patterns of protein kinase C isoenzymes are characteristically modulated in chronic pancreatitis and pancreatic cancer. Am J Clin Pathol 2003;119(3):392-402
   PubMedGoogle Scholar
• Gukovsky I, Li N, Todoric J, et al. Inflammation, autophagy, and obesity: common features in the pathogenesis of pancreatitis and pancreatic cancer. Gastroenterology 2013;144(6):1199-209. e1194
   PubMed Web of Science ®Google Scholar
• Fukuda A, Wang SC, Morris JP4th, et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 2011;19(4):441-55
   PubMed Web of Science ®Google Scholar
• Aziz MH, Hafeez BB, Sand JM, et al. Protein kinase Cvarepsilon mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression, and cell invasion in various human cancer cell lines through integration with MAPK cascade (RAF-1, MEK1/2, and ERK1/2). Oncogene 2010;29(21):3100-9
   PubMedGoogle Scholar
• Satoh A, Gukovskaya AS, Nieto JM, et al. PKC-delta and -epsilon regulate NF-kappaB activation induced by cholecystokinin and TNF-alpha in pancreatic acinar cells. Am J Physiol Gastrointest Liver Physiol 2004;287(3):G582-91
   Google Scholar
• Satoh A, Gukovskaya AS, Reeve JRJr, et al. Ethanol sensitizes NF-kappaB activation in pancreatic acinar cells through effects on protein kinase C-epsilon. Am J Physiol Gastrointest Liver Physiol 2006;291(3):G432-8
   Google Scholar
• Denham DW, Franz MG, Denham W, et al. Directed antisense therapy confirms the role of protein kinase C-alpha in the tumorigenicity of pancreatic cancer. Surgery 1998;124(2):218-23. discussion 223-214
   PubMedGoogle Scholar
• Chow JY, Dong H, Quach KT, et al. TGF-beta mediates PTEN suppression and cell motility through calcium-dependent PKC-alpha activation in pancreatic cancer cells. Am J Physiol Gastrointest Liver Physiol 2008;294(4):G899-905
   Google Scholar
• Chen Y, Yu G, Yu D, Zhu M. PKC alpha-induced drug resistance in pancreatic cancer cells is associated with transforming growth factor-beta1. J Exp Clin Cancer Res 2010;29:104
   PubMed Web of Science ®Google Scholar
• Way D, Smith S, Sivendran S, et al. A protein kinase C inhibitor induces phenotypic reversion of ras-transformed pancreatic cancer cells and cooperatively blocks tumor cell proliferation with an anti-ras peptide. Cancer Chemother Pharmacol 2002;49(6):429-37
   PubMedGoogle Scholar
• Detjen KM, Brembeck FH, Welzel M, et al. Activation of protein kinase Calpha inhibits growth of pancreatic cancer cells via p21(cip)-mediated G(1) arrest. J Cell Sci 2000;113(Pt 17):3025-35
   PubMed Web of Science ®Google Scholar
• Farrow B, Thomas RP, Wang XF, Evers BM. Activation of conventional PKC isoforms increases expression of the pro-apoptotic protein Bad and TRAIL receptors. Int J Gastrointest Cancer 2002;32(2-3):63-72
   PubMedGoogle Scholar
• El-Rayes BF, Ali S, Philip PA, Sarkar FH. Protein kinase C: a target for therapy in pancreatic cancer. Pancreas 2008;36(4):346-52
   PubMedGoogle Scholar
• Lam AP, Sparano JA, Vinciguerra V, et al. Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma. Am J Clin Oncol 2010;33(2):121-4
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Douillard JY, Koralewski P, et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2006;24(9):1428-34
   PubMed Web of Science ®Google Scholar
• Hanauske AR, Oberschmidt O, Hanauske-Abel H, et al. Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in in-vitro [corrected] soft-agar cloning experiments. Invest New Drugs 2007;25(3):205-10
   PubMed Web of Science ®Google Scholar
• Richards DA, Kuefler PR, Becerra C, et al. Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study. Invest New Drugs 2011;29(1):144-53
   PubMed Web of Science ®Google Scholar
• Johnson CL, Peat JM, Volante SN, et al. Activation of protein kinase C delta leads to increased pancreatic acinar cell dedifferentiation in the absence of MIST1. J Pathol 2012;228(3):351-65
   PubMedGoogle Scholar
• Ishino K, Fukazawa H, Shikano M, et al. Enhancement of anchorage-independent growth of human pancreatic carcinoma MIA PaCa-2 cells by signaling from protein kinase C to mitogen-activated protein kinase. Mol Carcinog 2002;34(4):180-6
   PubMedGoogle Scholar
• Mauro LV, Grossoni VC, Urtreger AJ, et al. PKC Delta (PKCdelta) promotes tumoral progression of human ductal pancreatic cancer. Pancreas 2010;39(1):e31-41
   PubMedGoogle Scholar
• Cheng J, Tian L, Ma J, et al. Dying tumor cells stimulate proliferation of living tumor cells via caspase-dependent protein kinase Cdelta activation in pancreatic ductal adenocarcinoma. Mol Oncol 2015;9(1):105-14
   PubMedGoogle Scholar
• Ohno I, Eibl G, Odinokova I, et al. Rottlerin stimulates apoptosis in pancreatic cancer cells through interactions with proteins of the Bcl-2 family. Am J Physiol Gastrointest Liver Physiol 2010;298(1):G63-73
   Google Scholar
• Chen Z, Forman LW, Miller KA, et al. Protein kinase Cdelta inactivation inhibits cellular proliferation and decreases survival in human neuroendocrine tumors. Endocr Relat Cancer 2011;18(6):759-71
   PubMed Web of Science ®Google Scholar
• Chen Z, Forman LW, Williams RM, Faller DV. Protein kinase C-delta inactivation inhibits the proliferation and survival of cancer stem cells in culture and in vivo. BMC Cancer 2014;14:90
   PubMedGoogle Scholar
• Souroujon MC, Mochly-Rosen D. Peptide modulators of protein-protein interactions in intracellular signaling. Nat Biotechnol 1998;16(10):919-24
   PubMed Web of Science ®Google Scholar
• Liron T, Chen LE, Khaner H, et al. Rational design of a selective antagonist of epsilon protein kinase C derived from the selective allosteric agonist, pseudo-RACK peptide. J Mol Cell Cardiol 2007;42(4):835-41
   PubMedGoogle Scholar
• Trauzold A, Schmiedel S, Sipos B, et al. PKCmu prevents CD95-mediated apoptosis and enhances proliferation in pancreatic tumour cells. Oncogene 2003;22(55):8939-47
   PubMed Web of Science ®Google Scholar
• Harikumar KB, Kunnumakkara AB, Ochi N, et al. A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther 2010;9(5):1136-46
   PubMed Web of Science ®Google Scholar
• Diaz-Meco MT, Lozano J, Municio MM, et al. Evidence for the in vitro and in vivo interaction of Ras with protein kinase C zeta. J Biol Chem 1994;269(50):31706-10
   PubMedGoogle Scholar
• Scotti ML, Bamlet WR, Smyrk TC, et al. Protein kinase Ciota is required for pancreatic cancer cell transformed growth and tumorigenesis. Cancer Res 2010;70(5):2064-74
   PubMedGoogle Scholar
• Leitges M, Sanz L, Martin P, et al. Targeted disruption of the zetaPKC gene results in the impairment of the NF-kappaB pathway. Mol Cell 2001;8(4):771-80
   PubMed Web of Science ®Google Scholar
• Muller G, Ayoub M, Storz P, et al. PKC zeta is a molecular switch in signal transduction of TNF-alpha, bifunctionally regulated by ceramide and arachidonic acid. EMBO J 1995;14(9):1961-9
   PubMedGoogle Scholar
• Nair SC, Pour PM, Lawson T, et al. Identification of protein kinase C zeta isozyme in hamster pancreas and pancreatic carcinoma cell lines. Mol Carcinog 1995;14(3):205-13
   PubMedGoogle Scholar
• Butler AM, Scotti Buzhardt ML, Li S, et al. Protein kinase C zeta regulates human pancreatic cancer cell transformed growth and invasion through a STAT3-dependent mechanism. PLoS One 2013;8(8):e72061
   Google Scholar
• Kato S, Akimoto K, Nagashima Y, et al. aPKClambda/iota is a beneficial prognostic marker for pancreatic neoplasms. Pancreatology 2013;13(4):360-8
   PubMedGoogle Scholar
• Yuan L, Seo JS, Kang NS, et al. Identification of 3-hydroxy-2-(3-hydroxyphenyl)-4H-1-benzopyran-4-ones as isoform-selective PKC-zeta inhibitors and potential therapeutics for psychostimulant abuse. Mol Biosyst 2009;5(9):927-30
   PubMedGoogle Scholar
• Wu J, Zhang B, Wu M, et al. Screening of a PKC zeta-specific kinase inhibitor PKCzI257.3 which inhibits EGF-induced breast cancer cell chemotaxis. Invest New Drugs 2010;28(3):268-75
   PubMedGoogle Scholar
• Kjaer S, Linch M, Purkiss A, et al. Adenosine-binding motif mimicry and cellular effects of a thieno [2,3-d] pyrimidine-based chemical inhibitor of atypical protein kinase C isoenzymes. Biochem J 2013;451(2):329-42
   PubMedGoogle Scholar
• Trujillo JI, Kiefer JR, Huang W, et al. 2-(6- Phenyl-1H-indazol-3-yl)-1H-benzo[d]imidazoles: design and synthesis of a potent and isoform selective PKC-zeta inhibitor. Bioorg Med Chem Lett 2009;19(3):908-11
   PubMed Web of Science ®Google Scholar
• Frohner W, Lopez-Garcia LA, Neimanis S, et al. 4-benzimidazolyl-3-phenylbutanoic acids as novel PIF-pocket-targeting allosteric inhibitors of protein kinase PKCzeta. J Med Chem 2011;54(19):6714-23
   PubMedGoogle Scholar
• Abdel-Halim M, Diesel B, Kiemer AK, et al. Discovery and optimization of 1,3,5-trisubstituted pyrazolines as potent and highly selective allosteric inhibitors of protein kinase C-zeta. J Med Chem 2014;57(15):6513-30
   PubMedGoogle Scholar
• Fields AP, Frederick LA, Regala RP. Targeting the oncogenic protein kinase Ciota signalling pathway for the treatment of cancer. Biochem Soc Trans 2007;35(Pt 5):996-1000
   PubMedGoogle Scholar
• Mansfield AS, Fields AP, Jatoi A, et al. Phase I dose escalation study of the PKCiota inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer. Anticancer Drugs 2013;24(10):1079-83
   PubMedGoogle Scholar
• Neesse A, Michl P, Frese KK, et al. Stromal biology and therapy in pancreatic cancer. Gut 2011;60(6):861-8
   PubMed Web of Science ®Google Scholar
• Cook N, Olive KP, Frese K, Tuveson DA. K-Ras-driven pancreatic cancer mouse model for anticancer inhibitor analyses. Methods Enzymol 2008;439:73-85
   PubMedGoogle Scholar
• Fu X, Herrera H, Hoffman RM. Orthotopic growth and metastasis of human prostate carcinoma in nude mice after transplantation of histologically intact tissue. Int J Cancer 1992;52(6):987-90
   PubMedGoogle Scholar
• Hiroshima Y, Zhao M, Maawy A, et al. Efficacy of Salmonella typhimurium A1-R versus chemotherapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX). J Cell Biochem 2014;115(7):1254-61
   PubMed Web of Science ®Google Scholar
• Suetsugu A, Katz M, Fleming J, et al. Multi-color palette of fluorescent proteins for imaging the tumor microenvironment of orthotopic tumorgraft mouse models of clinical pancreatic cancer specimens. J Cell Biochem 2012;113(7):2290-5
   PubMed Web of Science ®Google Scholar
• Suetsugu A, Katz M, Fleming J, et al. Non-invasive fluorescent-protein imaging of orthotopic pancreatic-cancer-patient tumorgraft progression in nude mice. Anticancer Res 2012;32(8):3063-7
   PubMed Web of Science ®Google Scholar
• Suetsugu A, Katz M, Fleming J, et al. Imageable fluorescent metastasis resulting in transgenic GFP mice orthotopically implanted with human-patient primary pancreatic cancer specimens. Anticancer Res 2012;32(4):1175-80
   PubMed Web of Science ®Google Scholar